Clinical cancer research : an official journal of the American Association for Cancer Research
ESR1 mutation in Endocrine treatment naive Endometrial Cancer: Prevalence, Characteristics and Prognostic Implications, results from the UTOLA phase II GINECO trial.
Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev, Raphael Leman, David N Church, Guillaume Beinse, Olivier Tredan, Leïla Bengrine Lefevre, Pierre-Emmanuel Brachet, Coriolan Lebreton, Guillaume Meynard, Pierre Fournel, Jean-Sébastien Frenel, Frédéric Selle, Corina Cornila
Published: 202610.1158/1078-0432.CCR-25-2758
Abstract
RATIONALE: Aromatase inhibitors (AIs) are used to treat estrogen receptor (ER)-positive low-grade endometrioid EC (LGEC). In breast cancer (BC), ESR1 mutations are rare at diagnosis (<5%) but are frequently acquired in of AI-resistant cases and are c…
Preview only. Read the full abstract at the source